Study Assessing QBS72S For Treating Brain Metastases
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05305365 |
Recruitment Status :
Recruiting
First Posted : March 31, 2022
Last Update Posted : February 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Metastases Breast Cancer | Drug: QBS72S | Phase 2 |
Primary Objective
1. Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through overall response rate (ORR) in Cohort 1 (Stages 1+2).
Secondary Objectives
- Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through progression free survival (PFS) in Cohort 1 (Stages 1+2).
- Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through overall survival (OS) in Cohort 1 (Stages 1+2).
- Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through durations of response (DoR) in Cohort 1 (Stages 1+2).
- Evaluate safety of QBS72S treatment in Cohort 1 (Stages 1+2), Cohort 2, and Cohort 3.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase IIa Study Assessing QBS72S For Treating Brain Metastases |
Actual Study Start Date : | August 16, 2022 |
Estimated Primary Completion Date : | February 2025 |
Estimated Study Completion Date : | August 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1)
All participants in Cohort 1 will receive QBS72S IV injections once monthly until disease progression.
|
Drug: QBS72S
QBS72S 18mg/m2 injection given intravenous once a month.
Other Name: QBS10072S |
Experimental: Patients with Breast Cancer Leptomeningeal Disease (Cohort 2)
All participants in Cohort 2 will receive QBS72S IV injections once monthly until disease progression.
|
Drug: QBS72S
QBS72S 18mg/m2 injection given intravenous once a month.
Other Name: QBS10072S |
Experimental: Patients with any Primary Cancer Leptomeningeal Disease (Cohort 3)
All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.
|
Drug: QBS72S
QBS72S 18mg/m2 injection given intravenous once a month.
Other Name: QBS10072S |
- Overall Response against Intracranial Tumor Lesions, Cohort 1 (Stages 1+2) [ Time Frame: 6 months ]The overall response against the target intracranial tumor lesions in Cohort 1 (Stages 1+2) participants was assessed by according to the modified Response Assessment in Neuro-oncology for Brain Metastases (mRANO-BM)
- RECIST 1.1 response criteria [ Time Frame: 6 months from the start of treatment ]Clinical response means either a complete response (CR) or a partial response (PR). CR is defined as disappearance of tumor lesions, and PR is defined as ≥ 30% reduction in diameter of tumor lesions.
- Progression-free Survival (PFS), Cohort 1 (Stages 1+2) [ Time Frame: 2 months ]Progression-free Survival (PFS) means to remain alive without tumor progression, assessed as a ≥ 25% increase in tumor diameter
- Overall Survival (OS), Cohort 1 (Stages 1+2) [ Time Frame: 2 months ]Overall survival (OS) refers to remaining alive at the time of the assessment.
- Duration of Response (DoR), Cohort 1 (Stages 1+2) [ Time Frame: 6 months ]Duration of Response (DoR) refers to length of time that a clinical response is maintained in Cohort 1 (Stages 1+2) participants.
- Related Adverse Events (AEs) [ Time Frame: 30 days following the last administration of study drug ]Toxicity refers to drug-related adverse events (AEs). The outcome is reported as the number of related AEs that were serious or non-serious, and by severity (mild, moderate, severe, life-threatening, or fatal), numbers without dispersion
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The participant must be 18 years or older
- The participant must have a Karnofsky Performance Status (KPS) of 60 or above.
-
One of the following:
- Cohorts 1 and 2: The participant must have a histologically-confirmed breast cancer primary tumor, either confirmed via primary specimen or via metastasis site, having developed brain metastases (parenchymal or LMD) after a prior cytotoxic chemotherapy regimen.
- Cohort 3: The participant must have a histologically cancerous primary tumor, either confirmed via primary specimen or via metastasis site, having developed brain metastases (parenchymal or LMD) after a prior cytotoxic chemotherapy regimen. There is no restriction on prior cycles of systemic therapy for any primary cancer type. Breast cancer is not excluded from Cohort 3.
-
One of the following:
- Cohort 1: A participant with breast cancer brain parenchymal tumors must have at least one nonirradiated tumor ≥ 3 mm2 that can be seen on 2 or more separate acquired brain MRI sequences.
- Cohort 2: A participant with breast cancer primary and
LMD must receive either:
i. a brain MRI with contrast that supports the presence of LMD, or ii. a CSF cytology test that is either positive for or suspicious for malignancy. The presence of parenchymal brain metastases does not exclude these participants from Cohort 2.
a. Cohort 3: A participant with LMD from any primary cancer site must receive either: i. a brain MRI with contrast that supports the presence of LMD, or ii. a CSF cytology test that is either positive for or suspicious for malignancy. The presence of parenchymal brain metastases does not exclude these participants from Cohort 3.
- For corticosteroids and anticonvulsants, the participant must either: c. not be taking any, or d. be taking stable or decreasing doses for ≥5 days prior to obtaining the screening Gd-MRI of the brain. The maximum allowable dose of corticosteroids is 8mg of dexamethasone per day, or the equivalent of another medication as assessed by a Neuro-Oncologist. Escalation of corticosteroids is not allowed ≤14 days prior to C1D1.
- The participant must have completed washout from prior therapy before C1D1, as applicable: e. ≥7 days for Ommaya placement (Cohorts 2+3) f. ≥14 days for small molecules and non-cytotoxic systemic drugs e.g., PARP inhibitors g. ≥21 days for checkpoint inhibitors and monoclonal antibodies, e.g., atezolizumab, pembrolizumab, and bevacizumab, and cytotoxic chemotherapy h. ≥28 days for investigational drugs, radiotherapy, and major surgery. Minor procedures such as tumor biopsy are allowed with written approval from the PI i. ≥1 dosing cycle for other interventions All significant toxicities from previous anticancer therapy must have stabilized to a new baseline or have resolved. Participation in long term follow up in another clinical trial is allowed if no procedures will be performed which may interfere with the interpretation of study results.
- The participant must have adequate bone marrow function, including: j. ANC ≥ 1,500/mm3 or ≥ 1.5 x 109/L k. Platelets ≥ 100,000/ mm3 or ≥ 100 x 109/L l. Hemoglobin ≥ 9 g/dL
- The participant must have adequate renal function, including serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min. In equivocal cases, a 24-hour urine collection test can be used to estimate the creatinine clearance more accurately.
- The participant must have adequate liver function, including: m. Total serum bilirubin ≤ 1.5 x ULN unless the participant has documented Gilbert syndrome who must have a total bilirubin < 3.0 mg/dl n. Aspartate and Alanine aminotransferase (AST and ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if there is liver involvement by the tumor
- Any participant physiologically capable of becoming pregnant or getting a partner pregnant must agree to use highly effective contraception during study treatment and for 7 months after study discontinuation.
- Participants or their designated advocates must be willing to and capable of providing informed consent and willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
Exclusion Criteria
- Participants with any other current, active malignancy unrelated to their primary cancer diagnosis, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ.
- Participants with intolerance to or who have had a severe (Grade 3) allergic or anaphylactic reaction to any of the substances included in the investigational product: sulfobutylether-β-cyclodextrin, melphalan, bendamustine, chlorambucil or any nitrogen mustard chemotherapeutics.
- Participants who currently use or have an anticipated need for a contraindicated medication including live vaccines, natalizumab, nivolumab, ocrelizumab, palifermin, pimecrolimus, tacrolimus, tofacitinib, and EIAEDs, including phenytoin, phenobarbital, carbamazepine, fosphenytoin, primidone, and oxcarbazepine. The washout period for any live vaccine is 30 days prior to enrollment. There is no restriction for seasonal flu vaccines that do not contain live virus, nor any approved COVID vaccine.
- Participants who are pregnant or breastfeeding.
- Participants who have active medical or psychiatric conditions which, in the opinion of the Principal Investigator or a Sub-Investigator, would compromise or interfere with their ability to participate in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05305365
Contact: Kriti Lalwani | 650-736-6489 | kritil@stanford.edu | |
Contact: Monica Granucci | 650-388-8906 | migranucci@stanford.edu |
United States, California | |
Stanford Cancer Institute | Recruiting |
Palo Alto, California, United States, 94305 | |
Contact: Monica Granucci 650-388-8906 migranucci@stanford.edu | |
Principal Investigator: Melanie H Gephart, MD, MAS | |
Sub-Investigator: Michael Iv, MD | |
Sub-Investigator: Seema Nagpal, MD | |
Sub-Investigator: Michael Lim, MD | |
Sub-Investigator: Gordon Li, MD | |
Sub-Investigator: Steven Chang, MD | |
Sub-Investigator: Lawrence Shuer, MD | |
Sub-Investigator: Reena Thomas, MD | |
Sub-Investigator: Chirag Patel, MD | |
Sub-Investigator: Melinda Telli, MD | |
Sub-Investigator: Michelle Melisko, MD |
Principal Investigator: | Melanie H Gephart, MD, MAS | Stanford University |
Responsible Party: | Melanie Hayden Gephart, Professor of Neurosurgery, Stanford University |
ClinicalTrials.gov Identifier: | NCT05305365 |
Other Study ID Numbers: |
IRB-63041 BRN0051 ( Other Identifier: OnCore ) NCI-2023-00648 ( Other Identifier: CTRP ) |
First Posted: | March 31, 2022 Key Record Dates |
Last Update Posted: | February 23, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplasm Metastasis Brain Neoplasms Neoplastic Processes Neoplasms Pathologic Processes Central Nervous System Neoplasms |
Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |